Ovarian Cancer PDX Models

The CrownBio ovarian cancer patient-derived xenograft (PDX) collection consists of several models including a treatment resistant model. PDX models present a true representation of the human heterogeneity of gynecologic malignancies and provide the most accurate approach to predicting an agents efficacy prior to entering the clinic. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
OV0243Ovarian CancerPapillary adenocarcinomaVIEW MODEL
OV0250Ovarian CancerEndometrioid adenocarcinomaVIEW MODEL
OV0273Ovarian CancerNAVIEW MODEL
OV0276Ovarian CancerADCVIEW MODEL
OV0589Ovarian CancerNAVIEW MODEL
OV1200Ovarian CancerADCVIEW MODEL
OV1272Ovarian CancercystadenomaVIEW MODEL
OV1286Ovarian CancerADCVIEW MODEL
OV1327Ovarian CancerSerous papillary cystadenocarcinomaVIEW MODEL
OV1365Ovarian CancerADCVIEW MODEL